KATHLEEN GRISSETT: Open Payments
NPI 1821170085 · ORANGE PARK, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,592 in 134 payments from 19 companies in 2025. Trend: 2023 $2,889 · 2024 $3,573 · 2025 $2,592
Food & beverage: $2,480Education: $111
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 17 | $407 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $296 |
| Otsuka America Pharmaceutical, Inc. | 15 | $241 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $230 |
| Axsome Therapeutics, Inc. | 9 | $194 |
| Alkermes, Inc. | 10 | $193 |
| Vanda Pharmaceuticals Inc. | 16 | $188 |
| Supernus Pharmaceuticals, Inc. | 13 | $147 |
| Corium, LLC | 8 | $147 |
| Collegium Pharmaceutical, Inc. | 6 | $113 |
Products named: VRAYLAR, CAPLYTA, TRINTELLIX, REXULTI, FANAPT, Auvelity, ARISTADA, Qelbree.
Industry payments across FL — which companies pay providers there.
